Also trades as: 0IV3.L (LSE) · $vol 0M
GERN NASDAQ
Geron Corporation
1W: -10.0%
1M: -18.7%
3M: -33.0%
YTD: -4.5%
1Y: -9.3%
3Y: -58.5%
5Y: -6.0%
$1.28
+0.02 (+1.59%)
Weekly Expected Move ±8.3%
$1
$1
$1
$1
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (37)
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
Geron (GERN) Q1 2026 Earnings Call Transcript
Earnings Scheduled For May 6, 2026
Geron targets $220M-$240M 2026 RYTELO net revenue while weighing new Europe commercialization models
Geron Reports Q1 2026 Results: Full Earnings Call Transcript
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron GAAP EPS of -$0.01 beats by $0.01, revenue of $51.84M beats by $1.25M
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Q1 2026 Earnings Preview
Geron Plans to Present at Upcoming Investor Conferences
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
Aberdeen Group plc Boosts Stock Holdings in Geron Corporation $GERN
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
Geron Announces Appointment of New Members to its Board of Directors
Almitas Capital LLC Buys Shares of 946,323 Geron Corporation $GERN
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings
Geron falls as Q4 results miss expectations
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Geron misses FY earnings result
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Here are the major earnings before the open Wednesday
Geron Q4 2025 Earnings Preview
Geron Plans to Present at Upcoming Investor Conferences
Earnings week ahead: NVDA, CRM, HD, BIDU, LOW, DELL, SNOW, AMC, ZM, and more
Geron (NASDAQ:GERN) Shares Down 6% – What’s Next?
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade)
Geron Corporation Provides 2026 Financial Guidance
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points